2016

Inactivation of Acanthamoeba spp. and Other Ocular Pathogens By Application of Cold Atmospheric Gas Plasma

Wayne Heaselgrave

Gilbert Shama

Peter W. Andrew

Michael G. Kong
Old Dominion University

Inactivation of *Acanthamoeba* spp. and Other Ocular Pathogens by Application of Cold Atmospheric Gas Plasma

Wayne Heaselgrave,[a] Gilbert Shama,[b] Peter W. Andrew,[c] Michael G. Kong[d]

University of Wolverhampton, School of Biomedical Science, Wolverhampton, United Kingdom[a]; University of Loughborough, Department of Chemical Engineering, Loughborough, Leicestershire, United Kingdom[b]; University of Leicester, Department of Infection, Immunity and Inflammation, Leicester, United Kingdom[c]; Old Dominion University, Frank Reidy Center for Bioelectrics, Norfolk, Virginia, USA[d]

Currently there are estimated to be approximately 3.7 million contact lens wearers in the United Kingdom and 39.2 million in North America. Contact lens wear is a major risk factor for developing an infection of the cornea known as keratitis due to poor lens hygiene practices. While there is an international standard for testing disinfection methods against bacteria and fungi (ISO 14729), no such guidelines exist for the protozoan *Acanthamoeba*, which causes a potentially blinding keratitis most commonly seen in contact lens wearers, and as a result, many commercially available disinfecting solutions show incomplete disinfection after 6 and 24 h of exposure. Challenge test assays based on international standard ISO 14729 were used to determine the antimicrobial activity of cold atmospheric gas plasma (CAP) against *Pseudomonas aeruginosa*, *Candida albicans*, and trophozoites and cysts of *Acanthamoeba polyphaga* and *Acanthamoeba castellanii*. *P. aeruginosa* and *C. albicans* were completely inactivated in 0.5 min and 2 min, respectively, and trophozoites of *A. polyphaga* and *A. castellanii* were completely inactivated in 1 min and 2 min, respectively. Furthermore, for the highly resistant cyst stage of both species, complete inactivation was achieved after 4 min of exposure to CAP. This study demonstrates that the CAP technology is highly effective against bacterial, fungal, and protozoan pathogens. The further development of this technology has enormous potential, as this approach is able to deliver the complete inactivation of ocular pathogens in minutes, in contrast to commercial multipurpose disinfecting solutions that require a minimum of 6 h.

Currently there are estimated to be approximately 3.7 million contact lens wearers in the United Kingdom (1) and 39.2 million in North America (2). Contact lens use is a major risk factor for developing an infection of the cornea known as keratitis (3, 4). Keratitis associated with contact lenses has been attributed to poor contact lens hygiene practices, including failure to comply with the manufacturers' guidelines, which includes the practice of "topping off" existing solution with a small amount of fresh solution in the lens case instead of discarding and using fresh solution each day (4–6).

The exact number of contact lens wearers developing keratitis worldwide is not known, but a recent study from the United States reported that there are estimated to be 930,000 doctors' appointments and 58,000 emergency appointments annually for keratitis in contact lens wearers, costing approximately $175 million in health care expenditure (7). The range of organisms causing keratitis is wide and includes the herpes simplex virus, bacteria, including *Pseudomonas aeruginosa*, fungi, including *Candida albicans*, and the protozoan *Acanthamoeba*, among many others.

Bacterial keratitis is frequently caused by the Gram-negative bacillus *P. aeruginosa*, and in a recent study conducted in India, this organism was found to be the causative agent in 29% of patients presenting with bacterial keratitis (8). A recent Danish study (9) implicated *C. albicans* in 52% of patients presenting with fungal keratitis.

Although bacteria and fungi are considered the main etiological agents for keratitis, the free-living protozoan *Acanthamoeba* can be an opportunistic pathogen of humans, causing a potentially blinding corneal infection known as *Acanthamoeba* keratitis (AK) (10, 11). *Acanthamoeba* has a virtually ubiquitous distribution in nature and can be found in most soil and aquatic environments, including gardens, household dust, heating systems, cool-

ing towers, lakes, rivers, and tap water (12–17). *Acanthamoeba* is a dimorphic organism that has two distinct life cycle stages: the motile feeding trophozoite stage and the dormant and highly resistant cyst stage (18). *Acanthamoeba* transforms into the cyst stage in response to adverse environmental conditions, including nutrient deprivation, exposure to various chemical agents, and changes in osmolarity (19–21). The cyst stage is highly resistant to both chemical disinfection and desiccation and remains viable and pathogenic even after decades in storage (22–24). There are currently no licensed drugs for treating AK, but unlicensed treatment does exist and consists of the application of a biguanide disinfectant— usually polyhexamethylene biguanide (PHMB) or chlorhexidine—and a diamidine directly to the eye. However, treatment times are long, and treatment failure is common (25).

The transformation of trophozoites into highly resistant cysts in response to adversity poses greater challenges to disinfection by multipurpose solutions (MPSs). This is due to the fact that great variability in the disinfecting efficacy against *Acanthamoeba* spp. has been reported between different commercially available MPSs, with many solutions delivering less than a 0.5-log reduc-

FIG 1 Schematic of the cold atmospheric gas plasma (CAP) apparatus in ambient air. The plasma is largely confined to the meshed ground electrode, and its reactive species are then transported, mostly through diffusion, to the downstream microbial sample.

tion in viability of the cyst stage (26–28). This lack of efficacy might be attributed to the current ISO guidelines, which outline the microbiological requirements and test methods for products and regimens for hygienic management of contact lenses but do not include efficacy testing standards against *Acanthamoeba* spp. (29). However, a standardized method has recently been proposed for assessing the biocidal efficacy of contact lens care solutions against cysts and trophozoites of *Acanthamoeba* (26). Despite this, many of the commercially available solutions lack any activity against *Acanthamoeba* cysts even after 6 h of exposure, which is the recommended disinfection time for most lens solutions.

Cold atmospheric gas plasmas (CAPs) are gas discharges at ambient pressure and at temperatures close to those of ambient conditions (30, 31). Treatment is usually defined in terms of time of exposure and the electrical power used to sustain the gas discharge. Their biological effects are attributed to the generation of a wide range of reactive oxygen species (ROS) and reactive nitrogen species (RNS). Gas plasmas have been shown to be capable of inactivating a wide range of microorganisms, including viruses, bacteria, and fungi (30, 31). However, protozoans have received little attention in this regard, and what studies have been conducted have focused on inactivation of the waterborne pathogen *Cryptosporidium* (32, 33). Therefore, we report here on the capability of a cold gas plasma against *Acanthamoeba polyphaga* and *Acanthamoeba castellanii*, in addition to the bacterial and fungal ocular pathogens *Pseudomonas aeruginosa* and *Candida albicans*, in order to establish whether its use could ultimately constitute the basis of a method for treating contact lenses.

MATERIALS AND METHODS

Chemicals. All chemicals were obtained from Sigma Chemical Company, Ltd. (Poole, United Kingdom), unless otherwise stated.

Test organisms and culture. *Pseudomonas aeruginosa* (ATCC 9027) and *Candida albicans* (ATCC 10231) were obtained from the American Type Culture Collection (LGC Standards, Teddington, United Kingdom). *P. aeruginosa* was cultured on tryptone soy agar and *C. albicans* on Sabouraud dextrose agar (Oxoid, Basingstoke, United Kingdom) for 24 h at 32°C to allow for colony formation. After incubation, suspensions of bacteria and fungi were prepared in 1/4-strength Ringer's solution to a concentration of 1×10^7 to 1×10^8 CFU/ml.

Acanthamoeba polyphaga (Puschkarew) Volkonsky (1931) (CCAP 1501/3g) was obtained from the Culture Collection of Algae and Protozoa (CCAP; Oban, United Kingdom). This is a clinical isolate obtained from a patient undergoing a keratoplasty in the United States in 1974. *Acanthamoeba castellanii* (Douglas) Page (ATCC 50370) was obtained from the

American Type Culture Collection (LGC Standards, Teddington, United Kingdom). This is a clinical isolate obtained from a keratitis patient in New York in 1978. Trophozoites of both species were adapted to growth in tissue culture flasks (Nunc Life Technologies, Paisley, United Kingdom) at 32°C in a semidefined axenic culture medium as described previously (34). Cysts were prepared from late-log-phase cultures using Neff's chemically defined encystment medium (35). Cysts were counted using a modified Fuchs Rosenthal hemocytometer, adjusted to 5×10^6/ml, and stored at 4°C for use within 2 weeks.

The CAP-generating apparatus. The CAP system used in the present study was an ambient air plasma confined to the surface of a sheet electrode of metallic mesh used as the ground electrode (36). A solid polymer plate was used to separate the ground electrode from the powered sheet electrode, and the electrode unit was powered at an electrical power density of 50 mW/cm² and at 20 kHz. With the ground electrode facing the microbial sample (described below), the electrode unit was suspended above the sample as shown in Fig. 1. Dominant ROS and RNS impinging on the sample included O_3, excited O_2, HO_2, H_2O_2, N_2O/HNO_2, NO_3/HNO_3, HNO_2, N_2O, and N_2O_5 (37).

Acanthamoeba **CAP assays.** Trophozoites from a late-log-phase suspension or cysts were counted using a modified Fuchs Rosenthal hemocytometer and adjusted to 5×10^4 cells in 20 ml of 1/4-strength Ringer's solution. The suspension containing the cysts or trophozoites was then poured into a filtration cup (Sartorius, Epsom, United Kingdom) that was attached to a manifold unit (Sartorius, Epsom, United Kingdom). The suspension was passed through a cellulose acetate filter with a 0.2-μm pore size (Pall, Portsmouth, United Kingdom). The purpose of the filtration step was to allow the organisms to settle onto the surface of the membrane and to be evenly distributed. The suction pressure was provided using a hand pump and was kept below 10 cm Hg to prevent excess suction stress and to prevent deformation and damage to the microorganisms. Once the filtration was complete, the cellulose acetate filter was removed aseptically from the suction cup using forceps and placed in the middle of the surface of an agar plate containing 2.5% (wt/vol) nonnutrient agar (NNA) no. 1 (Lab M, Bury, United Kingdom). The purpose of the agar was both to provide some moisture to prevent excess drying of the filter and to provide structural support to stop the filter from curling. Furthermore, the CAP-generating electrode had been fastened onto a petri dish lid and so fitted closely to the agar plates. The filters on the agar surface containing the microorganisms were exposed to the CAP-generating electrode for 0, 0.25, 0.5, 1, 2, 4, and 8 min. Each of the time points was performed using a separate filter in triplicate. The CAP apparatus was used in cycles of 30 s on and then 30 s off to prevent overheating, but the exposure time only relates to the time when the electrode was on. For example, a 1-min exposure was achieved by 30 s on, followed by 30 s off, followed by a further 30 s on.

After exposure to the CAP electrode for the specified time, the filter was removed from the surface of the agar and placed in a 50-ml centrifuge

TABLE 1 Efficacy of cold atmospheric gas plasma against *Pseudomonas aeruginosa* and *Candida albicans*

Pathogen	Condition[a]	Log$_{10}$ reduction in viability with exposure for[b]:			
		0.25 min	0.5 min	1 min	2 min
P. aeruginosa ATCC 9027	CAP	4.86	7.64*	7.64*	7.64*
	Control	0.06	0.06	0.06	0.06
C. albicans ATCC 10231	CAP	2.86	3.03	3.55	6.85*
	Control	0.00	0.01	0.01	0.02

[a] CAP, cold atmospheric gas plasma. Control experiments were performed in 1/4-strength Ringer's solution.
[b] Asterisks indicate complete inactivation.

TABLE 2 Efficacy of cold atmospheric gas plasma against trophozoites of *Acanthamoeba polyphaga* and *Acanthamoeba castellanii*

Pathogen	Condition[a]	Log$_{10}$ reduction in viability with exposure for[b]:			
		0.5 min	1 min	2 min	4 min
A. polyphaga CCAP 1501/3g	CAP	3.02	3.67*	3.67*	3.67*
	Control	0.00	0.00	0.00	0.00
A. castellanii ATCC 50370	CAP	2.00	3.51	3.67*	3.67*
	Control	0.00	0.00	0.02	0.08

[a] CAP, cold atmospheric gas plasma. Control experiments were performed in 1/4-strength Ringer's solution.
[b] Asterisks indicate complete inactivation.

tube containing 10 ml of 1/4-strength Ringer's solution, before being swabbed with a sterile cotton-tipped applicator (Puritan, Guilford, ME) to remove any adherent cells into the 1/4-strength Ringer's solution. The viability of the organisms was then determined using the previously published Spearman-Karber method, with minor modifications (34). Briefly, this involved transferring 200-µl aliquots of the *Acanthamoeba* suspension to the wells of a 96-well microtiter plate in quadruplet before performing three 10-fold serial dilutions of each. From the original concentration of cells, the serially diluted wells (10^0, 10^1, 10^2, and 10^3) would have contained approximately 1,000 cells, 100 cells, 10 cells, and 1 cell, respectively. The plates were examined microscopically for the presence of excysted trophozoites and/or trophozoite replication. The reduction in viable cysts or trophozoites was plotted as the change in log viability for each time point compared to zero time viability. All experiments were performed in triplicate.

Bacterial and fungal assays. The bacteria and fungi were tested according to the internationally recognized ISO 14729 method used for the evaluation of contact lens solutions against ocular pathogens (29), with modifications. Briefly, the organisms were cultured as stipulated in the ISO guidelines, and viable bacteria and fungi at a concentration of 1×10^7 were resuspended in 10 ml of 1/4-strength Ringer's solution. As for the *Acanthamoeba* assays, the suspensions were placed into the filter unit, and suction was applied to allow the organisms to settle onto the surface of the filter paper. The filter paper was then transferred to the surface of an agar plate for support and then exposed to the plasma.

After exposure to the plasma, the filters were removed from the agar and placed in a tube containing 10 ml 1/4-strength Ringer's solution. The surface of the cellulose acetate filter was swabbed aseptically to remove adherent organisms and then vortexed to bring about detachment of cells. To determine viability, the suspensions were serially diluted, and 50 µl of suspension for each dilution was cultured on the appropriate agar medium using the method of Miles and Misra (38). The reduction in viable cells was plotted as change in log viability for each time point compared to zero time viability, as described previously (39).

***Acanthamoeba* CAP contact lens assay.** For the contact lens assay, a Polymacon contact lens was placed convex side up on the surface of an NNA plate for support. The suspension of *A. castellanii* cysts was adjusted to 5×10^4 cells in 100 µl of 1/4-strength Ringer's solution. This suspension was then applied to the convex side of a Polymacon contact lens before exposure to plasma. The viability was then determined using the same method described for the *Acanthamoeba* CAP assay described above.

Data analysis. Statistical analysis was performed using one-way analysis of variance (ANOVA) of data from triplicate experiments on the InStat statistical software package (GraphPad, La Jolla, CA).

RESULTS

Bacterial and fungal assays. The effect of CAP against *Pseudomonas aeruginosa* and *Candida albicans* is shown in Table 1. CAP caused the complete inactivation (≥7-log reduction in viability)

of *P. aeruginosa* within 0.5 min of exposure, and with *C. albicans*, complete inactivation (6.85-log reduction in viability) was achieved after 2 min. Under control conditions in the absence of the plasma, a ≤0.06-log reduction in viability was observed for both organisms (Table 1). The log reductions observed with the CAP at complete inactivation for both organisms compared to the controls at the same time point were highly statistically significant ($P \leq 0.001$).

***Acanthamoeba* trophozoite assays.** The effect of CAP against trophozoites of *A. polyphaga* (CCAP 1501/3g) and *A. castellanii* (ATCC 50370) is shown in Table 2. CAP resulted in the complete inactivation (≥3.5-log reduction in viability) of *A. polyphaga* within 1 min, and with *A. castellanii*, this was achieved after 2 min of exposure. In control experiments in the absence of the plasma, a ≤0.08-log reduction in viability was observed for both strains of *Acanthamoeba* (Table 2). The log reductions observed with the CAP at complete inactivation for both organisms compared to the controls at the same time point were highly statistically significant ($P \leq 0.001$).

***Acanthamoeba* cyst assays.** The effect of CAP against cysts of *A. polyphaga* (CCAP 1501/3g) and *A. castellanii* (ATCC 50370) is shown in Table 3 and Fig. 2. CAP produced complete inactivation (≥3.5-log reduction in viability) of *A. polyphaga* within 4 min, and with *A. castellanii*, this was achieved after 2 min of exposure. For control experiments, a ≤0.08-log reduction in viability was observed for both strains of *Acanthamoeba* (Table 3). The log reductions observed with the CAP at complete inactivation for both organisms compared to the controls at the same time point were highly statistically significant ($P \leq 0.001$). The inactivation data from Table 3 for *A. castellanii* cysts have been plotted in Fig. 2 to

TABLE 3 Efficacy of cold atmospheric gas plasma against cysts of *Acanthamoeba polyphaga* and *Acanthamoeba castellanii*

Pathogen	Condition[a]	Log$_{10}$ reduction in viability with exposure for[b]:			
		0.5 min	1 min	2 min	4 min
A. polyphaga CCAP 1501/3g	CAP	0.00	1.50	3.59	3.75*
	Control	0.00	0.00	0.00	0.01
A. castellanii ATCC 50370	CAP	0.50	2.34	4.26	4.42*
	Control	0.00	0.02	0.03	0.06

[a] CAP, cold atmospheric gas plasma. Control experiments were performed in 1/4-strength Ringer's solution.
[b] Asterisks indicate complete inactivation.

FIG 2 Inactivation of *A. castellanii* cysts with cold atmospheric gas plasma (CAP). Error bars represent the standard error of the mean from triplicate experiments. Control experiments used 1/4-strength Ringer's solution alone.

reveal the form of the inactivation curve: a short "shoulder" occurs at low treatment times and is followed by a phase of rapid decline leading to complete inactivation.

Acanthamoeba contact lens assay. The effect of CAP against cysts of *A. castellanii* (ATCC 50370) on the surface of a Polymacon contact lens is shown in Table 4. CAP produced complete inactivation (≥3.5-log reduction in viability) of *A. castellanii* cysts after 12 min of exposure. The log reduction observed with the CAP at complete inactivation compared to that of the controls at the same time point was highly statistically significant ($P \leq 0.001$).

DISCUSSION

This study reveals that CAP can bring about the complete inactivation of all commonly encountered contact lens pathogens tested, including highly resistant cysts of *Acanthamoeba*. The predominant mechanism by which CAP brings about microbial inactivation is through the generation of both reactive oxygen species (ROS) and reactive nitrogen species (RNS), including O_3, excited O_2, HO_2, H_2O_2, N_2O/HNO_2, NO_3/HNO_3, HNO_2, N_2O, and N_2O_5 (37). The ocular pathogens investigated here included

the protozoans *A. polyphaga* and *A. castellanii*, the bacterium *P. aeruginosa*, and the yeast *C. albicans*. Treatment by the methods described here resulted in the complete inactivation of *P. aeruginosa* and *C albicans* in 0.5 min and 2 min, respectively. With trophozoites of *A. polyphaga* and *A. castellanii*, we were able to achieve complete inactivation in 1 min and 2 min, respectively. Furthermore, for the highly resistant cyst stage of both species, complete inactivation was achieved after 4 min of exposure to CAP.

CAP technology offers a significant performance advantage over current chemical disinfection methods, as supported by the finding in this study that complete disinfection of the test organisms was achieved in less than 4 min. In a recent study in which a number of commercial multipurpose solutions (MPSs) were tested against *P. aeruginosa* and *Fusarium solani*, a fungus included in the ISO testing guidelines (29), a >5-log reduction was obtained for both organisms with the commercial products ReNu MultiPlus (Bausch & Lomb, Rochester, NY) and OptiFree Express (Alcon, Ft. Worth, TX) that was achieved after the minimum disinfection times for these products of 4 and 6 h, respectively (40). In another recent study in which the efficacies of ReNu MultiPlus (Bausch & Lomb, Rochester, NY) and OptiFree RepleniSH (Alcon, Ft. Worth, TX) against *A. polyphaga* and *A. castellanii* were investigated, less than a 1-log reduction with cyst preparations even after 6 and 24 h of exposure to the solutions was achieved (26).

A number of disinfection methods for contact lenses that do not rely on the use of chemical compounds have been proposed in recent years. These include microwave treatment, sonication, and UV light treatment. Low-power microwave treatment was found to inactivate *P. aeruginosa*, *Staphylococcus aureus*, and *S. epidermi-*

TABLE 4 Efficacy of cold atmospheric gas plasma against cysts of *Acanthamoeba castellanii* on a Polymacon contact lens

Pathogen	Condition[a]	Log$_{10}$ reduction in viability with exposure for[b]:					
		2 min	4 min	6 min	8 min	10 min	12 min
A. castellanii ATCC 50370	CAP	1.25	1.33	1.33	1.50	3.52	3.84*
	Control	0.00	0.00	0.02	0.04	0.06	0.08

[a] CAP, cold atmospheric gas plasma. Control experiments were performed in 1/4-strength Ringer's solution.
[b] An asterisk indicates complete inactivation.

dis after 15 min (41). Microwave treatment was also shown to be effective in inactivating *Acanthamoeba* present on contact lens cases (42).

Although sonication has been proposed as a disinfection strategy (43), it has attracted relatively little interest. With reference to UV treatment, in a recent study from Johnson and Johnson Vision Care (Jacksonville, FL), reductions in viability of *Acanthamoeba* cysts were obtained that are comparable to those reported here (44). However, the times required to achieve a 3.8- to 4-log reduction in viability of the cysts using UV ranged from 18 to 21 min.

The possible effects of CAP treatment on the material of the contact lenses themselves lay outside the scope of the present study but constitute an important consideration that warrants future investigation. However, CAP may hold other benefits in addition to that of purely achieving disinfection. Lipids and other deposits from the eye are known to form on contact lenses and can impair cleanability as well as causing discomfort to wearers (45). It has been demonstrated that CAP proved superior to ultrasonic cleaning in removing stearic acid from polymer films (46). Moreover, it was reported in the same study that CAP treatment improved the wettability of the polymer—a factor that has been shown to be important in contact lens care (45).

In the present study, we restricted investigation to the direct exposure of the contact lenses to the plasma discharge, but this is not the only means by which treatment might be effected. In particular, it has been shown that certain plasma species survive in water sufficiently long enough to constitute an alternative way of achieving disinfection through contact with the plasma-treated water (47). In a completely different departure from the potential that CAPs possess for the disinfection of contact lenses, it was recently demonstrated that the application of CAP to the surface of the eye is able to bring about the rapid disinfection of bacteria and fungi from the ocular surface without causing damage to the corneal epithelium and stroma (48).

Further work would need to be undertaken to establish the precise configuration that a personalized CAP-based device for treating contact lenses would take. However, the availability of battery-powered CAP devices is at least a testament to the concept being feasible (49).

In conclusion, this study has demonstrated that the CAP technology is highly effective against the bacterial, fungal, and protozoan pathogens tested. The further development of this technology has considerable potential as this approach is able to deliver the complete inactivation of ocular pathogens in minutes compared to commercial multipurpose disinfecting solutions, which show variable and often incomplete activity after 6 and 24 h.

FUNDING INFORMATION

REFERENCES

1. **ACLM.** 2015. The ACLM contact lens year book 2014. Association of Contact Lens Manufacturers, Devizes, United Kingdom.
2. **Nichols JJ.** 2015. 2014 annual report: contact lenses. Contact Lens Spectrum **30:**22–27.
3. **Kilvington S, Heaselgrave W, Lally JM, Ambrus K, Powell H.** 2008. Encystment of Acanthamoeba during incubation in multipurpose contact lens disinfectant solutions and experimental formulations. Eye Contact Lens **34:**133–139. http://dx.doi.org/10.1097/ICL.0b013e3181772c95.
4. **Tu EY, Joslin CE.** 2010. Recent outbreaks of atypical contact lens-related keratitis: what have we learned? Am J Ophthalmol **150:**602–608.e2. http://dx.doi.org/10.1016/j.ajo.2010.06.045.
5. **Tu EY.** 2014. Acanthamoeba keratitis: a new normal. Am J Ophthalmol **158:**417–419. http://dx.doi.org/10.1016/j.ajo.2014.06.007.
6. **Verani JR, Lorick SA, Yoder JS, Beach MJ, Braden CR, Roberts JM, Conover CS, Chen S, McConnell KA, Chang DC, Park BJ, Jones DB, Visvesvara GS, Roy SL, Acanthamoeba Keratitis Investigation Team.** 2009. National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution, United States. Emerg Infect Dis **15:**1236–1242. http://dx.doi.org/10.3201/eid1508.090225.
7. **Collier SA, Gronostaj MP, MacGurn AK, Cope JR, Awsumb KL, Yoder JS, Beach MJ, Centers for Disease Control and Prevention.** 2014. Estimated burden of keratitis—United States, 2010. MMWR Morb Mortal Wkly Rep **63:**1027–1030.
8. **Mascarenhas J, Lalitha P, Prajna NV, Srinivasan M, Das M, D'Silva SS, Oldenburg CE, Borkar DS, Esterberg EJ, Lietman TM, Keenan JD.** 2014. Acanthamoeba, fungal, and bacterial keratitis: a comparison of risk factors and clinical features. Am J Ophthalmol **157:**56–62. http://dx.doi.org/10.1016/j.ajo.2013.08.032.
9. **Nielsen SE, Nielsen E, Julian HO, Lindegaard J, Hojgaard K, Ivarsen A, Hjortdal J, Heegaard S.** 2015. Incidence and clinical characteristics of fungal keratitis in a Danish population from 2000 to 2013. Acta Ophthalmol **93:**54–58. http://dx.doi.org/10.1111/aos.12440.
10. **Lorenzo-Morales J, Khan NA, Walochnik J.** 2015. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite **22:**10. http://dx.doi.org/10.1051/parasite/2015010.
11. **Marciano-Cabral F, Cabral G.** 2003. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev **16:**273–307. http://dx.doi.org/10.1128/CMR.16.2.273-307.2003.
12. **Barbeau J, Buhler T.** 2001. Biofilms augment the number of free-living amoebae in dental unit waterlines. Res Microbiol **152:**753–760. http://dx.doi.org/10.1016/S0923-2508(01)01256-6.
13. **Kilvington S, Gray T, Dart J, Morlet N, Beeching JR, Frazer DG, Matheson M.** 2004. Acanthamoeba keratitis: the role of domestic tap water contamination in the United Kingdom. Invest Ophthalmol Vis Sci **45:**165–169. http://dx.doi.org/10.1167/iovs.03-0559.
14. **Lorenzo-Morales J, Ortega-Rivas A, Foronda P, Martinez E, Valladares B.** 2005. Isolation and identification of pathogenic Acanthamoeba strains in Tenerife, Canary Islands, Spain from water sources. Parasitol Res **95:**273–277. http://dx.doi.org/10.1007/s00436-005-1301-2.
15. **Srikanth S, Berk SG.** 1993. Stimulatory effect of cooling tower biocides on amoebae. Appl Environ Microbiol **59:**3245–3249.
16. **Tsvetkova N, Schild M, Panaiotov S, Kurdova-Mintcheva R, Gottstein B, Walochnik J, Aspock H, Lucas MS, Muller N.** 2004. The identification of free-living environmental isolates of amoebae from Bulgaria. Parasitol Res **92:**405–413. http://dx.doi.org/10.1007/s00436-003-1052-x.
17. **Tyndall RL, Lyle MM, Ironside KS.** 1987. The presence of free-living amoebae in portable and stationary eye wash stations. Am Ind Hyg Assoc J **48:**933–934. http://dx.doi.org/10.1080/15298668791385831.
18. **Martinez AJ, Visvesvara GS.** 1997. Free-living, amphizoic and opportunistic amebas. Brain Pathol **7:**583–598. http://dx.doi.org/10.1111/j.1750-3639.1997.tb01076.x.
19. **Cordingley JS, Wills RA, Villemez CL.** 1996. Osmolarity is an independent trigger of Acanthamoeba castellanii differentiation. J Cell Biochem **61:**167–171.
20. **Lloyd D.** 2014. Encystment in Acanthamoeba castellanii: a review. Exp Parasitol **145**(Suppl):S20–S27. http://dx.doi.org/10.1016/j.exppara.2014.03.026.
21. **Lloyd D, Turner LA, Khunkitti W, Hann AC, Furr JR, Russell AD.** 2001. Encystation in *Acanthamoeba castellanii*: development of biocide resistance. J Eukaryot Microbiol **48:**11–16. http://dx.doi.org/10.1111/j.1550-7408.2001.tb00410.x.
22. **De Jonckheere J, van de Voorde H.** 1976. Differences in destruction of cysts of pathogenic and nonpathogenic Naegleria and Acanthamoeba by chlorine. Appl Environ Microbiol **31:**294–297.
23. **Mazur T, Hadas E, Iwanicka I.** 1995. The duration of the cyst stage and the viability and virulence of Acanthamoeba isolates. Trop Med Parasitol **46:**106–108.
24. **Sriram R, Shoff M, Booton G, Fuerst P, Visvesvara GS.** 2008. Survival of Acanthamoeba cysts after desiccation for more than 20 years. J Clin Microbiol **46:**4045–4048. http://dx.doi.org/10.1128/JCM.01903-08.
25. **Dart JK, Saw VP, Kilvington S.** 2009. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol **148:**487–499.e2. http://dx.doi.org/10.1016/j.ajo.2009.06.009.
26. **Kilvington S, Lam A.** 2013. Development of standardized methods for

assessing biocidal efficacy of contact lens care solutions against Acanthamoeba trophozoites and cysts. Invest Ophthalmol Vis Sci **54:**4527–4537. http://dx.doi.org/10.1167/iovs.13-11927.

27. **Lakhundi S, Khan NA, Siddiqui R.** 2014. Inefficacy of marketed contact lens disinfection solutions against keratitis-causing Acanthamoeba castellanii belonging to the T4 genotype. Exp Parasitol **141:**122–128. http://dx.doi.org/10.1016/j.exppara.2014.03.018.

28. **Shoff ME, Joslin CE, Tu EY, Kubatko L, Fuerst PA.** 2008. Efficacy of contact lens systems against recent clinical and tap water Acanthamoeba isolates. Cornea **27:**713–719. http://dx.doi.org/10.1097/QAI.0b013e31815e7251.

29. **ISO.** 2001. ISO/FDIS 14729, optics and optical instruments, contact lens care products, antimicrobial activity of products for disinfection of contact lenses. International Organization for Standardization, Geneva, Switzerland.

30. **Iza F, Kim GJ, Lee SM, K LJ, Walsh JL, Zhang YT, Kong MG.** 2008. Microplasmas: sources, particle kinetics and biomedical applications. Plasma Process Polymers **5:**322–344. http://dx.doi.org/10.1002/ppap.200700162.

31. **Shaw A, Shama G, Iza F.** 2015. Emerging applications of low temperature gas plasmas in the food industry. Biointerphases **10:**029402. http://dx.doi.org/10.1116/1.4914029.

32. **Hayes J, Kirf D, Garvey M, Rowan N.** 2013. Disinfection and toxicological assessments of pulsed UV and pulsed-plasma gas-discharge treated-water containing the waterborne protozoan enteroparasite Cryptosporidium parvum. J Microbiol Methods **94:**325–337. http://dx.doi.org/10.1016/j.mimet.2013.07.012.

33. **Vassal S, Favennec L, Ballet JJ, Brasseur P.** 1998. Hydrogen peroxide gas plasma sterilization is effective against Cryptosporidium parvum oocysts. Am J Infect Control **26:**136–138. http://dx.doi.org/10.1016/S0196-6553(98)80032-1.

34. **Hughes R, Kilvington S.** 2001. Comparison of hydrogen peroxide contact lens disinfection systems and solutions against Acanthamoeba polyphaga. Antimicrob Agents Chemother **45:**2038–2043. http://dx.doi.org/10.1128/AAC.45.7.2038-2043.2001.

35. **Neff RJ, Ray SA, Benton WF, Wilbourn M.** 1964. Induction of synchronous encystment (differentiation) in *Acanthamoeba* sp. Methods Cell Physiol **1:**55–83.

36. **Li D, Liu DX, Nie Q, Xu D, Li Q, Kong MG.** 2014. Emission characteristics of surface microdischarge in atmospheric-pressure He/N$_2$ mixture. IEEE Trans Plas Sci **42:**2640–2641. http://dx.doi.org/10.1109/TPS.2014.2321431.

37. **Liu ZC, Liu DX, Chen C, Li D, Yang AJ, Rong MZ, Chen HL, Kong MG.** 2015. Physicochemical processes in the indirect interaction between surface air plasma and deionized water. J Phys D Appl Phys **48:**495201. http://dx.doi.org/10.1088/0022-3727/48/49/495201.

38. **Miles AA, Misra SS.** 1938. The estimation of the bactericidal power of the blood. J Hyg (Lond) **38:**732–749. http://dx.doi.org/10.1017/S002217240001158X.

39. **Hughes R, Dart J, Kilvington S.** 2003. Activity of the amidoamine myristamidopropyl dimethylamine against keratitis pathogens. J Antimicrob Chemother **51:**1415–1418. http://dx.doi.org/10.1093/jac/dkg259.

40. **Siddiqui R, Lakhundi S, Khan NA.** 2015. Status of the effectiveness of contact lens solutions against keratitis-causing pathogens. Cont Lens Anterior Eye **38:**34–38. http://dx.doi.org/10.1016/j.clae.2014.09.001.

41. **Kastl PR, Maehara JR.** 2001. Low-power microwave disinfection of soft contact lenses. CLAO J **27:**81–83.

42. **Hiti K, Walochnik J, Faschinger C, Haller-Schober EM, Aspock H.** 2001. Microwave treatment of contact lens cases contaminated with acanthamoeba. Cornea **20:**467–470. http://dx.doi.org/10.1097/00003226-200107000-00005.

43. **Harris MG, Rechberger J, Grant T, Holden BA.** 1990. In-office microwave disinfection of soft contact lenses. Optom Vis Sci **67:**129–132. http://dx.doi.org/10.1097/00006324-199002000-00012.

44. **Lonnen J, Putt KS, Kernick ER, Lakkis C, May L, Pugh RB.** 2014. The efficacy of Acanthamoeba cyst kill and effects upon contact lenses of a novel ultraviolet lens disinfection system. Am J Ophthalmol **158:**460–468.e2. http://dx.doi.org/10.1016/j.ajo.2014.05.032.

45. **Guillon M, Maissa C, Wong S, Patel T, Garofalo R.** 2015. Effect of lens care system on silicone hydrogel contact lens wettability. Cont Lens Anterior Eye **38:**435–441. http://dx.doi.org/10.1016/j.clae.2015.06.007.

46. **Gotoh K, Yu N, Tagawa Y.** 2013. Evaluation of removal of model particulate and oily soils from poly(ethylene terephthalate) films by microscopic image analysis. J Oleo Sci **62:**73–79. http://dx.doi.org/10.5650/jos.62.73.

47. **Naitali M, Kamgang-Youbi G, Herry JM, Bellon-Fontaine MN, Brisset JL.** 2010. Combined effects of long-living chemical species during microbial inactivation using atmospheric plasma-treated water. Appl Environ Microbiol **76:**7662–7664. http://dx.doi.org/10.1128/AEM.01615-10.

48. **Brun P, Brun P, Vono M, Venier P, Tarricone E, Deligianni V, Martines E, Zuin M, Spagnolo S, Cavazzana R, Cardin R, Castagliuolo I, Valerio AL, Leonardi A.** 2012. Disinfection of ocular cells and tissues by atmospheric-pressure cold plasma. PLoS One **7:**e33245. http://dx.doi.org/10.1371/journal.pone.0033245.

49. **Mitra A, Morfill GE, Shimizu T, Steffes B, Isbary I, Schmidt H, Li Y, Zimmermann JL.** 2012. Applications in plasma medicine: a SWOT approach. Compos Interfaces **19:**231–238. http://dx.doi.org/10.1080/15685543.2012.700200.